A Guide Through the Tunnel: Updates in the Approach to Classification and Management of Perianal Fistulizing Crohn's Disease
- PMID: 40576852
- DOI: 10.1007/s11894-025-00998-0
A Guide Through the Tunnel: Updates in the Approach to Classification and Management of Perianal Fistulizing Crohn's Disease
Abstract
Purpose of review: Perianal fistulizing Crohn's disease (PFCD) is a severe and debilitating phenotype of Crohn's disease that presents significant clinical and therapeutic challenges. This review aims to outline a practical approach to classification and management, emphasizing the utility of the TOpClass system.
Recent findings: The TOpClass classification incorporates clinical and anatomic characteristics to assess severity, treatment options, and patient-clinician goals. Post-hoc analyses from clinical trials for the Janus kinase inhibitor Upadacitinib and emerging data on IL-23 receptor antagonists suggest potential roles beyond anti-TNFs, while the broader use of mesenchymal stem cell therapy remains limited due to inconsistent efficacy. Fistula conditioning with curettage and internal opening closure-an underutilized technique-alongside adjunctive therapies such as hyperbaric oxygen therapy (HBOT), has shown promise in promoting wound healing in select patients. The TOpClass classification, by integrating patient-centered factors and multidisciplinary management, offers a comprehensive and adaptable framework for PFCD, addressing key gaps in treatment planning, standardization, and research. The classification will enable tailored, evidence-based care across the disease spectrum.
Keywords: Crohn’s disease; Perianal fistula; Perianal fistulizing Crohn’s disease; TOpClass classification.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing Interests: Author SYW reports research contract with Takeda/Trinetx; advisory board - Bristol Myers Squibb; and support - Eli Lilly and Company.
Similar articles
-
Perianal Fistulizing Crohn's Disease-Associated Anorectal and Fistula Cancers: Systematic Review and Expert Consensus.Clin Gastroenterol Hepatol. 2025 May;23(6):927-945.e2. doi: 10.1016/j.cgh.2024.05.029. Epub 2024 Jun 12. Clin Gastroenterol Hepatol. 2025. PMID: 38871152
-
Treatment of perianal fistula in Crohn's disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment.Colorectal Dis. 2016 Jul;18(7):667-75. doi: 10.1111/codi.13311. Colorectal Dis. 2016. PMID: 26921847
-
Perianal Fistulizing Crohn's Disease: Utilizing the TOpClass Classification in Clinical Practice to Provide Targeted Individualized Care.Clin Gastroenterol Hepatol. 2025 May;23(6):914-926. doi: 10.1016/j.cgh.2024.06.047. Epub 2024 Aug 10. Clin Gastroenterol Hepatol. 2025. PMID: 39134293 Review.
-
Efficacy and safety of FiLaC™ for perianal fistulizing Crohn's disease: a systematic review and meta-analysis.Tech Coloproctol. 2022 Oct;26(10):775-781. doi: 10.1007/s10151-022-02682-1. Epub 2022 Aug 12. Tech Coloproctol. 2022. PMID: 35962294
-
Long-term outcomes of fistula-tract laser closure for complex perianal fistulizing Crohn's disease.Tech Coloproctol. 2024 Jul 31;28(1):89. doi: 10.1007/s10151-024-02949-9. Tech Coloproctol. 2024. PMID: 39085710
References
-
- American Gastroenterological Association Clinical Practice C. American gastroenterological association medical position statement: perianal crohn’s disease. Gastroenterology. 2003;125(5):1503–7.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials